Figure 2. Reduction in ear length along both the anteroposterior and mediolateral axes in Vismodegib treated tadpoles.

A) The reduction in ear length along anteroposterior, mediolateral, and dorsoventral axes followed a linear dose response curve. This decrease in ear size was more profound along the anteroposterior dimension of the ear compared to the mediolateral or dorsoventral dimension of the ear. While ears from animals treated with 12.5 μM and greater doses of Vismodegib were significantly reduced in length along the anteroposterior axis from controls, only 18.75 μM and 21.875 μM Vismodegib-treated animals were significantly reduced along the mediolateral axis from controls. The reduction in length along the anteroposterior axis at the highest dose of Vismodegib was approximately 2-fold, whereas along the mediolateral axis, it was only approximately 1.3-fold. B) Illustration of lengths measured along the anteroposterior axis and mediolateral axis in the ear of a stage 46 control tadpole. C) Illustration of lengths measured along the anteroposterior axis and mediolateral axis in the ear of a stage 46 tadpole treated with 21.875 μM Vismodegib. Scale bars represent 100μm. D) The reduction in approximate volume as calculated from the anteroposterior, mediolateral, and dorsoventral lengths from each ear followed a linear dose response curve. The volumes of animals treated with 18.75 μM and 21.875 μM Vismodegib were significantly reduced to approximately 1/4^th the volume of controls. * p<0.05, ** p<0.01, ***P<0.001, ****p<0.0001 (ANOVA).